Transcatheter Aortic Valve Replacement for Left Ventricular Assist Device-Induced Aortic Insufficiency.

SURGICAL AORTIC VALVE replacement historically has been the standard of care for patients with severe, symptomatic aortic stenosis. However, up to one-third of patients with symptomatic aortic stenosis are not surgical candidates because of medical comorbidities, left ventricular dysfunction, or advanced age. 1 Leon M.B. Smith C.R. Mack M. et al. Transcatheter aortic-valve implantation for aorticstenosis in patients who cannot undergo surgery. N Engl J Med. 2010; 363: 1597-1607 Crossref PubMed Scopus (5441) Google Scholar In the past, inoperable patients had received medical management with poor outcomes, highlighting the need for a different intervention. Transcatheter aortic valve replacement (TAVR) first gained widespread attention in 2002, when Cribier et al implanted the first valve in a human recipient. 2 Cribier A. Eltchaninoff H. Bash A. et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description. Circulation. 2002; 106: 3006-3008 Crossref PubMed Scopus (2574) Google Scholar Since then, approximately 200,000 patients have undergone the procedure to treat native valve aortic stenosis. 3 Puri R. Rodes-Cabau J. Transcatheter aortic valve replacement: A revolution in evolution. JACC Cardiovasc Interv. 2016; 9: 364-366 Crossref PubMed Scopus (7) Google Scholar